VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) has scheduled its Second Quarter 2025 Earnings Conference Call and Business Update for Friday, August 15, 2025, at 8:30 a.m. Eastern Time. The call will be hosted by key executives including Louise Batchelor (Group Chief Marketing & Communications Officer), Cameron Reynolds (President and CEO), Terig Hughes (CFO), and Dr. Andrew Retter (Chief Medical Officer).
The conference call will be accessible via multiple channels, including toll-free numbers for U.S., Canada, and U.K. participants, as well as a live audio webcast. A replay will be available until August 29, 2025. The event will cover Q2 2025 financial results and provide updates on recent developments and upcoming milestones.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VNRX
On the day this news was published, VNRX gained 0.45%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to take place on Friday, August 15 at 8:30 a.m.
Event: VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call
Date: Friday, August 15, 2025
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13755349
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in the second quarter of 2025 and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until August 29, 2025. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-second-quarter-2025-earnings-conference-call-and-business-update-302525234.html
SOURCE VolitionRx Limited